HRT: What the Evidence Actually Says (And Why the Fear Needs Updating)

Hormone Replacement Therapy has been through three decades of controversy, a landmark study that caused millions of women to stop treatment abruptly, and a slow, evidence-driven rehabilitation that most mainstream media has not yet caught up with. If you are confused about HRT – whether it is safe, whether you should consider it, what the actual risks are – you are not confused because you have not done enough research. You are confused because the public messaging has been contradictory, fear-driven, and often wrong.

This guide will not tell you what to do. That decision belongs to you and a doctor who knows your history. What it will do is give you an accurate picture of what the evidence actually says, so you can have an informed conversation rather than walking in afraid.

What Is HRT?

Hormone Replacement Therapy (also called Menopause Hormone Therapy or MHT) replaces the oestrogen and, where appropriate, progesterone that decline during the menopause transition. The goal is to reduce or eliminate the symptoms driven by that decline: hot flushes, night sweats, sleep disruption, vaginal dryness, joint pain, mood changes, brain fog, and reduced bone density.

HRT comes in several forms: tablets, patches, gels, sprays, and vaginal preparations. The delivery method matters clinically – transdermal preparations (patches, gels, sprays) bypass the liver and carry a different risk profile to oral tablets, particularly regarding blood clot risk.

The WHI Study: What It Actually Found

In 2002, the Womens Health Initiative (WHI) study published results that caused an immediate collapse in HRT prescribing. The study reported increased risks of breast cancer, heart disease, stroke, and blood clots. Millions of women stopped HRT overnight on medical advice.

What was not communicated clearly at the time: the WHI study used a specific combination of synthetic hormones (conjugated equine oestrogen + medroxyprogesterone acetate, in oral tablet form) in women whose average age was 63 – over a decade past menopause. The results do not straightforwardly apply to women using modern HRT preparations at perimenopause or early postmenopause, which is when most women use it.

Subsequent analysis of the WHI data and multiple independent studies have substantially revised the risk picture. The medical consensus among menopause specialists has shifted significantly – but the fear created by the 2002 headlines persists in public understanding and in some GP surgeries.

What the Current Evidence Shows

Breast cancer risk: The most cited concern. For combined HRT (oestrogen + progesterone), the risk increase is real but modest – roughly comparable to drinking one to two glasses of wine daily, and smaller than the risk from obesity or physical inactivity. Oestrogen-only HRT (for women who have had a hysterectomy) does not appear to increase breast cancer risk, and some studies suggest it may reduce it. The type of progesterone matters: micronised progesterone (body-identical) carries a lower risk than synthetic progestogens.

Cardiovascular risk: Transdermal oestrogen started within 10 years of menopause or before age 60 (the “timing hypothesis” or “window of opportunity”) appears to be cardioprotective in most women, not harmful. The heart disease risk seen in the WHI was associated with oral oestrogen in older women started long after menopause.

Blood clot (VTE) risk: Oral HRT increases VTE risk. Transdermal HRT does not appear to increase this risk, including in women who would otherwise be considered higher risk. This is a clinically significant distinction.

Bone protection: HRT is highly effective at preserving bone density and reducing fracture risk – an underappreciated benefit given the significant mortality and morbidity associated with osteoporotic fractures in older women.

Dementia and cognitive protection: Emerging evidence suggests oestrogen therapy started around the time of menopause may have a protective effect on cognitive function and dementia risk. This remains an active research area.

Who HRT Is Generally Suitable For

Most women in perimenopause or early postmenopause with troublesome symptoms. Women with premature ovarian insufficiency (POI) or early menopause are especially encouraged to use HRT until the average age of natural menopause (around 51), given the health consequences of prolonged oestrogen deficiency.

Who Should Discuss Alternatives With a Specialist

Women with a personal history of hormone-receptor-positive breast cancer, certain blood clotting disorders, or active liver disease require specialist review before HRT. These are not automatic exclusions in all cases, but they require careful individualised discussion.

How to Have the Conversation With Your Doctor

Come prepared with your symptoms (keep a brief diary for two to four weeks before the appointment), your personal and family medical history, and your questions. Ask specifically about transdermal options and body-identical hormones. If your GP is not familiar with current menopause guidance, asking for a referral to a menopause specialist is reasonable and appropriate.

You deserve a decision based on your individual circumstances and current evidence – not on a 2002 news cycle.

Recommended Reading

• The Menopause Mindset: Navigating the Change With Clarity and Confidence – The emotional and psychological navigation of menopause alongside the physical. Coming Soon – Strong Through Change
• The Menopause Strength Blueprint: Rebuilding Your Body, Mind and Energy – Practical strategies for thriving through and beyond the menopause transition. Coming Soon – Strong Through Change